MERCOSUR is an open and dynamic process. Since its creation, its main objective has been to promote a common space that generates business and investment opportunities through the competitive integration of national economies into the international market. MERCOSUR is the Customs Union between the States Parties to the Southern Common Market. Its full members are Argentina, Brazil, Paraguay, and Uruguay. Venezuela is a full member but has been suspended since 1 December 2016. Associate member countries are Bolivia, Chile, Colombia, Ecuador, Guyana, Peru and Suriname.

On 5 May 2021, by means of the Decree 297, the Argentinian Government incorporated a series of bio-based products to the Common External Tariff (Arancel Externo Común, A.E.C) list. The aim is to establish differential rates of Extra-zone Import Duties (Derechos de Importación Extrazona, DIE).

According to Pharmabiz, the Indian pharmaceutical industry portal, which conducted a special investigation to identify which laboratories are affected, it emerged that there are six active substances of innovator biological products or biosimilars which will be charged with a tariff of 14% as from May 2021, see Table 1. So, it will mainly be the laboratories with Latin equity that have long been inclined to invest in the biosimilars business that will be mostly favoured.

  
Related articles
Prices for arthritis biologicals in Latin America

Relieving the economic burden on EU healthcare budgets: spotlight on IV trastuzumab and rituximab biosimilars

  
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.